Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Oxazolidinone Antibiotics (LCB01-0371)_LegoChem.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Oxazolidinone Antibiotics (LCB01-0371)...
Contact Yong U Kim
Email me a copy of this message


Characteristics of antibiotics market

1. Most big pharma companies are active in the market and there is no single market-leading drug or class. Instead, a number of blockbusters from different classes and for different indications are dominating the scene.

- total sales : $25.5 billion (7 major markets in 2005), CAGR : 5.1% (2001~2005)

2. The antibiotics market is highly genericized but branded products still account for the main part of sales.

- branded products : 73% total sales achieved with as little as 19% of total prescription volume (US in 2005)

3. Although the community market is still dominant, the hospital market is gaining importance.

- the hospital market has been gaining sales market share with a CAGR of 8.8% (2001~2005)


MRSA drugs are a main source of overall antibacterial market growth

Growth drivers : increasing incidence, emerging resistances, high drug prices

Expected CAGR 2005-2015 : 14.8%



1. Oral MRSA drugs: With MRSA incidence rising in the community, oral drugs have a large commercial potential.




2. Gram-negative resistance: Carbapenems and tigecycline are the only available treatment options for severe gram-negative infections. Upon emergence of resistances, novel drugs are a crucial need.




3. Compounds outside previous drug classes: Most compounds currently in development are derivatives of existing drugs with low potential to overcome resistances in the mid- to long term.



Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE